Citius Pharmaceuticals, Inc. (CTXR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US17322U3068
Citius Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -38.53 m USD |
| EBIT | -38.53 m USD |
| Net income | -37.43 m USD |
| Diluted EPS – continuing operations | -3.38 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
More stocks
- Bridger Aerospace Group Holdings, Inc. (BAER)
- Investcorp Credit Management BDC, Inc. (ICMB)
- Security Midwest Bancorp, Inc. (SBMW)
- American Strategic Investment Co. (NYC)
- FIREFLY NEUROSCIENCE, INC. (AIFF)
- Creative Media & Community Trust Corp (CMCT)
- NextTrip, Inc. (NTRP)
- Marker Therapeutics, Inc. (MRKR)
- Local Bounti Corporation/DE (LOCL)
- QUOTEMEDIA INC (QMCI)
- ARTS WAY MANUFACTURING CO INC (ARTW)
- KEY TRONIC CORP (KTCC)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.